Royce & Associates’s Novavax NVAX Stock Holding History

Royce & Associates’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-19,500	Closed	-$819K	–	1244
2018 Q1	$819K	Sell	19,500 -8,000	-29%	-$321K	0.01%	1002
2017 Q4	$682K	Hold	27,500	–	–	﹤0.01%	1021
2017 Q3	$627K	Hold	27,500	–	–	﹤0.01%	1015
2017 Q2	$633K	Hold	27,500	–	–	﹤0.01%	1027
2017 Q1	$704K	Hold	27,500	–	–	﹤0.01%	1019
2016 Q4	$693K	Sell	27,500 -17,500	-39%	-$510K	﹤0.01%	981
2016 Q3	$1.87M	Buy	+45,000	New	+$5.81M	0.01%	823

Other funds holding NVAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's NVAX Position: Q2 2018 in Review

Royce & Associates sold out of Novavax (NVAX) in Q2 2018, closing a stake of 19,500 shares — an estimated $819K sold.

Royce & Associates first reported a position in NVAX in Q3 2016 and held it in 7 quarters. The position peaked at $1.87M in Q3 2016. 156 funds tracked by Wall St. Rank hold NVAX as of Q2 2018.

Royce & Associates reported no remaining Novavax position as of Q2 2018 after selling out during the quarter.
Royce & Associates sold 19,500 Novavax shares in Q2 2018, an estimated $819K.
Royce & Associates first reported a position in Novavax in Q3 2016 and held it in 7 quarters.
Royce & Associates's Novavax position peaked at $1.87M in Q3 2016.
156 funds tracked by Wall St. Rank held Novavax as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.